Appendix 1. RECONNECT Study Design. During the screening month, hypoactive sexual desire disorder diagnosis was confirmed. The placebo self-dosing month allowed establishment of the placebo effect. Placebo-responders were not excluded in this trial, but baseline was established at the end of the placebo self-dosing month. After this, subjects received either bremelanotide or placebo during the randomized, double-blind core phase. Participants self-administered bremelanotide 1.75 mg or placebo subcutaneously using an autoinjector pen, as needed. Participants who completed the core phase and remained eligible were given the option to continue in the open-label extension and receive bremelanotide 1.75 mg subcutaneously on an as-needed basis.



BMT, bremelanotide; OLE, open-label extension.

Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol 2019;134.
The authors provided this information as a supplement to their article.

Appendix 2. Efficacy Assessments

Instrument	Measure	Items and Domains	Type of Test
Female Sexual Function Index (FSFI)	Female sexual dysfunction	19 items in 6 domains, including desire, arousal, lubrication, orgasm, satisfaction, and pain. Scores from 2–36	4-week recall
Female Sexual Distress Scale–Desire/Arousal/Orgasm (FSDS-DAO)	Sexual distress	15-item instrument based on FSDS–Revised (FSDS-R). Scores from 0–60	Likert-like response scale; 4-week recall
General Assessment Questionnaire (GAQ)	Satisfaction level	4 items related to satisfaction level: 1. satisfaction with arousal 2. satisfaction with desire 3. degree of benefit while on study drug 4. impact of taking study drug on relationship with partner	Each item uses a 7-point numeric rating scale from 1 (very much worse) to 4 (no change) to 7 (very much better); assessed at each monthly clinic visit; Item 3 asks, "Compared with the start of the study (prior to taking the study drug), to what degree do you think you benefited from taking the study drug?" (a score ≥5 indicates benefit)

*A "sexual encounter" was defined as any act involving sexual contact with genitalia and/or oral mucosa, and included intercourse, oral sex, and masturbation by self or a partner.

Appendix 3. Exposure to Bremelanotide 1.75 mg

	Study 301		Study 302	
	Placebo (N=239)	BMT 1.75 mg (N=124)	Placebo (N=191)	BMT 1.75 mg (N=130)
Median injections in core phase (range)	0	14 (6, 43)	0	13.5 (5, 47)
Median injections in OLE phase (range)	12 (1, 120)	11 (1, 77)	13 (1, 105)	10 (1, 68)
Median total injections overall (range)	12 (1, 120)	27 (8, 106)	13 (1, 105)	25 (9, 104)
Mean duration of exposure (SD), days	220.0 (142.6)	408.8 (140.6)	229.2 (138.2)	407.0 (135.9)

BMT, bremelanotide; OLE, open-label extension; SD, standard deviation.